Held G - Search Results

1

Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas.

Achenbach M, Bittenbring JT, Ziepert M, Regitz E, Ott G, Rosenwald A, Pfreundschuh M, Altmann B, Held G. Achenbach M, et al. Among authors: held g. Br J Haematol. 2014 Nov;167(3):430-4. doi: 10.1111/bjh.13001. Epub 2014 Jun 27. Br J Haematol. 2014. PMID: 24974897 Free article. No abstract available.

2

Cure of disseminated xenografted human Hodgkin's tumors by bispecific monoclonal antibodies and human T cells: the role of human T-cell subsets in a preclinical model.

Renner C, Bauer S, Sahin U, Jung W, van Lier R, Jacobs G, Held G, Pfreundschuh M. Renner C, et al. Among authors: held g. Blood. 1996 Apr 1;87(7):2930-7. Blood. 1996. PMID: 8639913 Free article.

3

T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.

Renner C, Ohnesorge S, Held G, Bauer S, Jung W, Pfitzenmeier JP, Pfreundschuh M. Renner C, et al. Among authors: held g. Blood. 1996 Jul 1;88(1):236-41. Blood. 1996. PMID: 8704179 Free article.

4

Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies.

Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M. Renner C, et al. Among authors: held g. Immunobiology. 1997 Jun;197(1):122-32. doi: 10.1016/S0171-2985(97)80062-9. Immunobiology. 1997. PMID: 9241536

5

Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo.

Bauer S, Renner C, Juwana JP, Held G, Ohnesorge S, Gerlach K, Pfreundschuh M. Bauer S, et al. Among authors: held g. Cancer Res. 1999 Apr 15;59(8):1961-5. Cancer Res. 1999. PMID: 10213507

6

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.

Hartmann F, Renner C, Jung W, da Costa L, Tembrink S, Held G, Sek A, König J, Bauer S, Kloft M, Pfreundschuh M. Hartmann F, et al. Among authors: held g. Clin Cancer Res. 2001 Jul;7(7):1873-81. Clin Cancer Res. 2001. PMID: 11448899 Clinical Trial.

7

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.

Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY, Tai TY, Cohen CJ, Old LJ, Pfreundschuh M, Reiter Y, Hoogenboom HR, Renner C. Held G, et al. Eur J Immunol. 2004 Oct;34(10):2919-29. doi: 10.1002/eji.200425297. Eur J Immunol. 2004. PMID: 15368308 Free article.

8

Rituximab for the treatment of diffuse large B-cell lymphomas.

Held G, Pöschel V, Pfreundschuh M. Held G, et al. Expert Rev Anticancer Ther. 2006 Aug;6(8):1175-86. doi: 10.1586/14737140.6.8.1175. Expert Rev Anticancer Ther. 2006. PMID: 16925484 Review.

9

Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas.

Held G, Schubert J, Reiser M, Pfreundschuh M; German High-Grade Non-Hodgkin-Lymphoma Study Group. Held G, et al. Semin Hematol. 2006 Oct;43(4):221-9. doi: 10.1053/j.seminhematol.2006.07.003. Semin Hematol. 2006. PMID: 17027656 Review.

10

Identification of antigenic targets of paraproteins by expression cloning does not support a causal role of chronic antigenic stimulation in the pathogenesis of multiple myeloma and MGUS.

Preuss KD, Held G, Kubuschok B, Hung CZ, Malatsidze N, Wagner M, Pfreundschuh M. Preuss KD, et al. Among authors: held g. Int J Cancer. 2007 Jul 15;121(2):459-61. doi: 10.1002/ijc.22686. Int J Cancer. 2007. PMID: 17373665 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

227 results

Search Page

Filters